Kawanishi Hideki, Moriishi Misaki
Tsuchiya General Hospital, Hiroshima, Japan.
Perit Dial Int. 2007 Jun;27 Suppl 2:S289-92.
Since the first peritoneal dialysis (PD) patients with encapsulating peritoneal sclerosis (EPS) were reported in 1980, EPS has been considered primarily a fatal complication. The incidence of EPS in PD patients has been reported to be 2.5%, with a negative effect of increasing PD duration (which also augments mortality). Because EPS occurs after withdrawal from PD in more than half of all cases, strict monitoring is necessary when a long-term PD patient is withdrawn from PD. Maintaining patients on standard PD with conventional solutions for more than 8 years is associated with a substantial risk of EPS development. Treatment appropriate to the disease stage is most important in EPS. Basic therapeutic strategies for EPS include the appropriate use of steroids. If bowel obstruction persists, laparotomy and enterolysis should be performed to achieve a complete cure. It is now recognized that EPS need not be a fatal complication of PD.
自1980年首次报道腹膜透析(PD)患者发生包裹性腹膜硬化症(EPS)以来,EPS一直被视为主要的致命并发症。据报道,PD患者中EPS的发生率为2.5%,其对PD持续时间的延长有负面影响(这也会增加死亡率)。由于超过半数的EPS病例发生在停止PD治疗之后,因此当长期PD患者停止PD治疗时,严格监测是必要的。使用传统溶液进行标准PD治疗超过8年的患者发生EPS的风险显著增加。针对疾病阶段进行适当治疗在EPS中最为重要。EPS的基本治疗策略包括适当使用类固醇。如果肠梗阻持续存在,应进行剖腹手术和肠粘连松解术以实现完全治愈。现在人们认识到,EPS不一定是PD的致命并发症。